Cargando…
Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic
Patients with inflammatory diseases who receive moderate or high-risk anti-inflammatory therapies might be considered as an increased risk group for severe COVID-19 and appropriate measures should be taken in order to protect them. . Initiation of immuno-suppressive/modulatory therapies should be do...
Autores principales: | Apostolou, Theofanis, Koutroubakis, Ioannis E., Manolakopoulos, Spilios, Mantzaris, Gerasimos, Rigopoulos, Dimitrios, Triantafyllou, Konstantinos, Vassilopoulos, Dimitrios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Mediterranean Journal of Rheumatology (MJR)
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656124/ https://www.ncbi.nlm.nih.gov/pubmed/33196008 http://dx.doi.org/10.31138/mjr.31.3.295 |
Ejemplares similares
-
Public Statement on the Importance of Prevention and Management of Obesity and Metabolic Syndrome during the COVID-19 Pandemic
por: Lee, Chang Beom
Publicado: (2021) -
Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document()
por: Kumar, Saurabh, et al.
Publicado: (2020) -
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
por: Bachanova, Veronika, et al.
Publicado: (2020) -
Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022) -
ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic
por: Stolbach, Andrew I., et al.
Publicado: (2020)